Cargando…

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor

INTRODUCTION: Modulation of Factor XIa (FXIa) may provide a novel mechanism for systemic anticoagulation with the potential to improve the risk-benefit profile observed with existing anticoagulants through greater efficacy or a safer bleeding profile. This study assessed the effects of co-administra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perera, Vidya, Wang, Zhaoqing, Lubin, Susan, Christopher, Lisa J., Chen, Wei, Xu, Sophia, Seiffert, Dietmar, DeSouza, Mary, Murthy, Bindu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381674/ https://www.ncbi.nlm.nih.gov/pubmed/35641780 http://dx.doi.org/10.1007/s40119-022-00266-6

Ejemplares similares

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2021)

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
por: Perera, Vidya, et al.
Publicado: (2022)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

Corrigendum: First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
Publicado: (2022)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Kim, Minsoo, et al.
Publicado: (2019)

Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis
por: Wang, Xinkang, et al.
Publicado: (2023)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
por: Merali, Samira J., et al.
Publicado: (2023)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
por: Chen, Rui, et al.
Publicado: (2022)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
por: Thomas, Dirk, et al.
Publicado: (2019)

Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis
por: Dhoot, Dhiraj, et al.
Publicado: (2023)

Effect of Itraconazole on the Pharmacokinetics of Diclofenac in Beagle Dogs
por: Al-Jenoobi, Fahad I.
Publicado: (2010)

Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
por: Jansen, Anouk M E, et al.
Publicado: (2023)

Decision making in xia2
por: Winter, Graeme, et al.
Publicado: (2013)

In Memorium of Dr. Bing Xia
por: Qian, Jiaming, et al.
Publicado: (2015)

Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Safety and Efficacy of Prehospital Diltiazem
por: Luk, Jeffrey H., et al.
Publicado: (2013)

Diltiazem-associated Photodistributed Hyperpigmentation
por: Siegel, Jacob D., et al.
Publicado: (2020)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

In Vitro–In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of Its Metabolite
por: Mircioiu, Constantin, et al.
Publicado: (2019)

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012)

Diltiazem-Induced Reversible Cardiogenic Shock in Thyroid Storm
por: Sakaan, Rami A, et al.
Publicado: (2021)

Death from diltiazem–ibrutinib interaction
por: Falconer, Nazanin, et al.
Publicado: (2021)

Diltiazem for clozapine-induced generalized hyperhidrosis
por: Kenton, Emma M., et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
por: Wang, Li, et al.
Publicado: (2022)

Xia-Gibbs Syndrome: A Review of Literature
por: Goyal, Chanan, et al.
Publicado: (2020)

Impact of Diltiazem Alone versus Diltiazem with Nitrate on Five-Year Clinical Outcomes in Patients with Significant Coronary Artery Spasm
por: Park, Taeshik, et al.
Publicado: (2017)

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
por: Moore, Katy, et al.
Publicado: (2019)

Recalcitrant generalized pustular eruption after diltiazem
por: Jandhyala, Sridhar, et al.
Publicado: (2012)

Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases
por: Rodríguez Padial, Luis, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ck9gt83q3f9k5hllcldbfq0k5a